- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03601078
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma (KarMMa-2)
A Phase 2, Multi-cohort, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With Clinical High-Risk Multiple Myeloma (KarMMa-2)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: BMS Study Connect Contact Center www.BMSStudyConnect.com
- Phone Number: 855-907-3286
- Email: Clinical.Trials@bms.com
Study Contact Backup
- Name: First line of the email MUST contain the NCT# and Site #.
Study Locations
-
-
-
Poitiers, France, 86021
- Recruiting
- Local Institution - 404
-
Contact:
- Site 404
-
-
-
-
-
Hamburg, Germany, 20246
- Completed
- Local Institution - 506
-
Würzburg, Germany, 97080
- Recruiting
- Local Institution - 505
-
Contact:
- Site 505
-
-
-
-
-
Bologna, Italy, 40138
- Completed
- Local Institution - 603
-
-
-
-
-
Pamplona, Spain, 31008
- Recruiting
- Local Institution - 703
-
Contact:
- Site 703
-
Salamanca, Spain, 37007
- Recruiting
- Local Institution - 704
-
Contact:
- Site 704
-
-
-
-
-
London, United Kingdom, SE5 9RS
- Recruiting
- Local Institution - 801
-
Contact:
- Site 801
-
-
-
-
Arizona
-
Scottsdale, Arizona, United States, 85259
- Recruiting
- Mayo Clinic in Arizona - Scottsdale
-
Contact:
- Leif Bergsagel, Site 151
-
-
California
-
San Francisco, California, United States, 94143
- Recruiting
- University of California San Francisco Medical Center
-
Contact:
- Alfred Chung, Site 152
- Phone Number: 000-000-0000
-
-
Florida
-
Tampa, Florida, United States, 33612
- Recruiting
- Moffitt Cancer Center
-
Contact:
- Melissa Alsina, Site 153
- Phone Number: 813-745-6886
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Emory University School of Medicine
-
Contact:
- Madhav Dhodapkar, Site 149
- Phone Number: 203-785-2604
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Recruiting
- Beth Israel Deaconess Medical Center
-
Contact:
- David Avigan, Site 159
- Phone Number: 617-794-9101
-
Boston, Massachusetts, United States, 02117
- Recruiting
- Massachusetts General Hospital
-
Contact:
- Noopur Raje, Site 146
- Phone Number: 617-726-0711
-
Boston, Massachusetts, United States, 02215-5450
- Recruiting
- Dana Farber Cancer Institute
-
Contact:
- Adam Sperling, Site 145
- Phone Number: 617-632-4218
-
Boston, Massachusetts, United States, 02118
- Withdrawn
- Local Institution - 0802
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- Washington University
-
Contact:
- Ravi Vij, Site 156
- Phone Number: 314-454-8304
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198-7680
- Recruiting
- University of Nebraska
-
Contact:
- Christopher Dangelo, Site 155
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Recruiting
- John Theurer Cancer Center at Hackensack University Medical Center
-
Contact:
- David Siegel, Site 144
- Phone Number: 551-996-8704
-
-
New York
-
New York, New York, United States, 10032
- Recruiting
- Columbia University Medical Center/New York-Presbyterian Hospital
-
Contact:
- Ran Reshef, Site 157
- Phone Number: 212-342-0530
-
New York, New York, United States, 10029
- Recruiting
- Mt Sinai Medical Center - NY
-
Contact:
- Shambavi Richard, Site 154
- Phone Number: 212-241-7873
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28204
- Recruiting
- Levine Cancer Institute
-
Contact:
- Barry Paul, Site 150
- Phone Number: 980-442-2000
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Recruiting
- Sarah Cannon Research Inst
-
Contact:
- Jesus Berdeja, Site 142
- Phone Number: 615-329-0570
-
-
Texas
-
Dallas, Texas, United States, 75390
- Recruiting
- University of Texas Southwestern Medical Center
-
Contact:
- Larry Anderson, Site 148
- Phone Number: 214-648-5906
-
Houston, Texas, United States, 77030
- Recruiting
- MD Anderson Cancer Center The University of Texas
-
Contact:
- Krina Patel, Site 147
- Phone Number: 713-792-6662
-
-
Washington
-
Seattle, Washington, United States, 98104
- Recruiting
- Swedish Cancer Inst
-
Contact:
- Daniel Egan, Site 143
- Phone Number: 617-699-2437
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Recruiting
- Froedtert Hospital BMT Medical College of Wisconsin
-
Contact:
- Meera Mohan, Site 158
- Phone Number: 414-805-4600
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Subjects must satisfy the following criteria to be enrolled in the study:
- Subject is ≥ 18 years of age at the time of signing the informed consent form (ICF)
For Cohorts 1 and 2 only, participant has measurable disease, defined as:
- M-protein (serum protein electrophoresis [sPEP] or urine protein electrophoresis [uPEP]): sPEP ≥ 0.5 g/dL or uPEP ≥ 200 mg/24 hours and/or
- Light chain MM without measurable disease in the serum or urine: Serum immunoglobulin free light chain ≥ 10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio
Subjects with one of the following cohort specific requirements:
Cohort 1 RRMM subjects with ≥ 3 prior anti-myeloma treatment regimens:
- Subject must have received at least 3 prior anti-myeloma treatment regimens. Note: induction with or without hematopoietic stem cell transplant and with or without maintenance therapy is considered a single regimen
- Subject must have undergone at least 2 consecutive cycles of treatment for each regimen, unless PD was the best response to the regimen
- Subject must have received prior treatment with a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody
- Subject has evidence of PD on or within 60 days of the most recent prior treatment regimen
- Subject achieved a response (minimal response [MR] or better) to at least 1 prior treatment regimen
Cohort 2 subjects with 1 prior anti-myeloma treatment regimen:
- Subject must have received only 1 prior anti-myeloma treatment regimen. Note: induction with or without hematopoietic stem cell transplant and with or without maintenance therapy is considered a single regimen
- Subject must have the following HR factors:
- Early relapse defined as:
Cohort 2a: PD < 18 months since date of start of initial therapy. Initial therapy must contain induction, ASCT (single or tandem) and lenalidomide containing maintenance.
Cohort 2b: PD < 18 months since date of start or initial therapy which must contain at minimum, a proteasome inhibitor, an immunomodulatory agent and dexamethasone Cohort 2c: Subject must have received minimum 3 cycles of induction therapy which must contain at minimum, a proteasome inhibitor, an immunomodulatory agent and dexamethasone. Subjects must have had ASCT (single or tandem AND < VGPR (excluding PD) at first assessment between 70 to 110 days after last ASCT, with initial therapy without consolidation and maintenance.
Cohort 3 participants with newly diagnosed MM (NDMM) who received only induction and ASCT, without subsequent consolidation or maintenance Cohort 3
- Must have received 4 to 6 cycles of induction therapy which must contain at minimum, a proteasome inhibitor and an immunomodulatory agent and must have had single ASCT within 6 months prior to consent
- Must have achieved documented PR or VGPR at first post-ASCT assessment approximately 100 days after ASCT and this response must be maintained at screening
- Per Investigator's assessment, subject must be a candidate for single-agent lenalidomide maintenance
- Subject must have Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
- Subject must have recovery to Grade 1 or baseline of any non-hematologic toxicities due to prior treatments, excluding alopecia and Grade 2 neuropathy
Exclusion Criteria:
The presence of any of the following will exclude a subject from enrollment:
- Subject used any investigational agents within 14 days prior to leukapheresis or, for Cohort 3, within 14 days prior to consent
Subject received any of the following within the last 14 days prior to leukapheresis or, for Cohort 3, within 14 days prior to consent:
- Plasmapheresis
- Major surgery (as defined by the investigator)
- Radiation therapy other than local therapy for myeloma associated bone lesions
- Use of any systemic anti-myeloma drug therapy
- Subject with known central nervous system involvement with myeloma
- Subject has clinical evidence of pulmonary leukostasis and disseminated intravascular coagulation
- History or presence of clinically relevant central nervous system (CNS) pathology
- Subject with active or history of plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome, or clinically significant amyloidosis
- Inadequate organ function Subject with a history of Class III or IV congestive heart failure (CHF) or severe nonischemic cardiomyopathy, unstable or poorly controlled angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months prior to starting study treatment
- Ongoing treatment with chronic immunosuppressants
- Previous history of an allogeneic hematopoietic stem cell transplantation or treatment with any gene therapy-based therapeutic for cancer or investigational cellular therapy for cancer or BCMA targeted therapy
- Subject has received ASCT within 12 weeks prior to leukapheresis
- Subject has history of primary immunodeficiency
- Subject is positive for human immunodeficiency virus (HIV-1), chronic or active hepatitis B or active hepatitis A or C
- Subject has uncontrolled systemic fungal, bacterial, viral or other infection (including tuberculosis) despite appropriate antibiotics or other treatment
- Subject with prior history of malignancies, other than MM, unless the subject has been free of the disease for ≥ 5 years
- Pregnant or lactating women
- Subject with known hypersensitivity to any component of bb2121 product, cyclophosphamide, fludarabine, and/or tocilizumab
- Prior history of deep venous thrombosis (DVT) or pulmonary embolus (PE) within 6 months prior to consent (For Cohort 3)
- For Cohort 1b, previous treatment with any G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D) targeted therapy or T-cell engagers
- For Cohort 1b, known allergies, hypersensitivity, or intolerance to talquetamab or its excipients
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1: BB2121 in relapsed and refractory multiple myeloma participants
bb2121 autologous CAR T cells will be infused at a dose ranging from 150 - 450 x 10^6 CAR+ T cells after receiving lymphodepleting chemotherapy
|
bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR)
Other Names:
|
Experimental: Cohort 1b: BB2121 with talquetamab in relapsed and refractory multiple myeloma participants
|
bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR)
Other Names:
Specified dose on specified days
Other Names:
|
Experimental: Cohort 2a: BB2121 in multiple myeloma with Autologous stem cell transplantation participants
|
bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR)
Other Names:
|
Experimental: Cohort 2b: BB2121 in multiple myeloma without Autologous stem cell transplantation participants
|
bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR)
Other Names:
|
Experimental: Cohort 2c: BB2121 in multiple myeloma participants with inadequate response post ASCT
|
bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR)
Other Names:
|
Experimental: Cohort 3: BB2121 with lenalidomide maintenance in newly diagnosed multiple myeloma
|
bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR)
Other Names:
Specified dose on specified days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate (ORR)- Cohort 1
Time Frame: Up to approximately 5 years
|
Percentage of subjects who achieved partial response (PR) or better according to IMWG Uniform Response Criteria for Multiple Myeloma as assessed by the investigator
|
Up to approximately 5 years
|
Complete response (CR) rate - Cohort 1b, 2a, 2b, 2c, and Cohort 3
Time Frame: Up to approximately 5 years
|
Percentage of subjects who achieved CR or stringent CR according to IMWG Uniform Response Criteria for Multiple Myeloma as assessed by the investigator
|
Up to approximately 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete response (CR) rate - Cohort 1
Time Frame: Up to approximately 5 years
|
Percentage of subjects who achieved CR or better according to IMWG Uniform Response Criteria for Multiple Myeloma as assessed by the investigator
|
Up to approximately 5 years
|
Very good partial response (VGPR) rate - Cohort 2c
Time Frame: Up to approximately 5 years
|
Percentage of subjects who achieved VGPR or better according to IMWG Uniform Response Criteria for Multiple Myeloma as assessed by the investigator
|
Up to approximately 5 years
|
Time to response (TTR)
Time Frame: Up to approximately 5 years
|
Time from first bb2121 infusion to first documentation of response (PR or greater) [Cohorts 1 and 2]; time from first dose of lenalidomide pre-leukapheresis to first documentation of response [Cohort 3 only]
|
Up to approximately 5 years
|
Duration of response (DoR)
Time Frame: Up to approximately 5 years
|
Time from first documentation of response (PR or greater) to first documentation of progressive disease (PD) or death from any cause, whichever occurs first
|
Up to approximately 5 years
|
Progression-free survival (PFS)
Time Frame: Up to approximately 5 years
|
Time from first bb2121 infusion to first documentation of PD, or death due to any cause, whichever occurs first (Cohorts 1 and 2); time from first dose of lenalidomide pre-leukapheresis to first documentation of PD, or death due to any cause, whichever occurs first (Cohort 3 only)
|
Up to approximately 5 years
|
Time to progression (TTP)
Time Frame: Up to approximately 5 years
|
Time from first bb2121 infusion to first documentation of PD (Cohorts 1 and 2); time from first dose of lenalidomide pre-leukapheresis to first documentation of PD (Cohort 3 only)
|
Up to approximately 5 years
|
Overall survival (OS)
Time Frame: Up to approximately 5 years
|
Time from first bb2121 infusion to time of death due to any cause (Cohorts 1 and 2); time from first dose of lenalidomide pre-leukapheresis to time of death due to any cause (Cohort 3 only)
|
Up to approximately 5 years
|
Adverse Events (AEs)
Time Frame: Up to approximately 5 years
|
Type, frequency, seriousness and severity of adverse events (AEs), adverse events of special interest (AESIs) (including cytokine release syndrome, neurotoxicity and infection), and relationship of AE to study drug.
|
Up to approximately 5 years
|
Percentage of participants who received lenalidomide maintenance for the first 3 cycles following bb2121 infusion with at least 75% dose compliance - Cohort 3
Time Frame: Up to 3 months
|
Up to 3 months
|
|
Pharmacokinetics - Cmax
Time Frame: Minimum 5 years after bb2121 infusion
|
Maximum expansion of bb2121 chimeric antigen receptor (CAR) T cells
|
Minimum 5 years after bb2121 infusion
|
Pharmacokinetics - tmax
Time Frame: Minimum 5 years after bb2121 infusion
|
Time to peak of bb2121 CAR T cells
|
Minimum 5 years after bb2121 infusion
|
Pharmacokinetics - AUC
Time Frame: Minimum 5 years after bb2121 infusion
|
Area under the curve of CAR T cells
|
Minimum 5 years after bb2121 infusion
|
Pharmacokinetics - tlast
Time Frame: Minimum 5 years after bb2121 infusion
|
Time to last measurable CAR T cells
|
Minimum 5 years after bb2121 infusion
|
Pharmacokinetics - AUC0-28days
Time Frame: Minimum 5 years after bb2121 infusion
|
Area under the curve of CAR T cells from time zero to Day 28
|
Minimum 5 years after bb2121 infusion
|
Immunogenicity
Time Frame: Minimum of 2 years after bb2121 infusion
|
Development of an anti-CAR antibody response
|
Minimum of 2 years after bb2121 infusion
|
Subject-reported outcomes as measured by European Organization for Research and Treatment of Cancer Quality-of-Life questionnaire (EORTC-QLQ-C30)
Time Frame: Minimum 5 years after bb2121 infusion
|
Questionnaire will be used as a measure of health-related quality of life
|
Minimum 5 years after bb2121 infusion
|
Subject-reported outcomes as measured by EuroQoL Group EQ-5D-5L Health Questionnaire
Time Frame: Minimum 5 years after bb2121 infusion
|
Is a standardized measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal
|
Minimum 5 years after bb2121 infusion
|
Subject-reported outcomes as measured by EORTC-QLQ-MY20
Time Frame: Minimum 5 years after bb2121 infusion
|
Is a 20-item myeloma module intended for use among patients varying in disease stage and treatment modality
|
Minimum 5 years after bb2121 infusion
|
Overall response rate (ORR) - Cohort 1b, 2a, b, c and Cohort 3
Time Frame: Up to approximately 5 years
|
Percentage of subjects who achieved partial response (PR) or better according to IMWG Uniform Response Criteria for Multiple Myeloma as assessed by the investigator
|
Up to approximately 5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Idecabtagene vicleucel
Other Study ID Numbers
- BB2121-MM-002
- U1111-1216-4209 (Other Identifier: WHO)
- 2018-000264-28 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on bb2121
-
CelgeneAvailable
-
CelgeneCompletedMultiple MyelomaUnited States, Canada, Belgium, France, Germany, Italy, Japan, Spain
-
Memorial Sloan Kettering Cancer CenterRecruiting
-
CelgeneActive, not recruitingMultiple MyelomaUnited States, Spain
-
Marcelo Pasquini, MDNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsActive, not recruiting
-
CelgeneCompletedMultiple MyelomaUnited States
-
Bristol-Myers SquibbRecruitingMultiple MyelomaAustria, Spain, Australia, United States, Japan, France, Israel, Italy, Greece, Belgium, Norway, Romania, Poland, Canada, Czechia, Denmark, Germany, Korea, Republic of, United Kingdom
-
CelgeneActive, not recruitingMultiple MyelomaUnited States, Belgium, Canada, France, Germany, Italy, Japan, Netherlands, Norway, Spain, Sweden, Switzerland, United Kingdom